Treats myasthenia gravis. ANDA 205650, held by Zydus Pharms. Pyridostigmine Bromide.
As of Nov 16, 2026, ANDA 205650 (Pyridostigmine Bromide), held by Zydus Pharms, was first approved by FDA on Jun 22, 2015, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Pyridostigmine bromide tablets, USP are useful in the treatment of myasthenia gravis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 22, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Pyridostigmine Bromide60MG · tablet;oral | Pyridostigmine Bromide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters